Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ELANE | P08246 | 13/20 | 0.65 |
| ▸ | CA1 | P00915 | 1/20 | 0.48 |
| ▸ | CA2 | P00918 | 1/20 | 0.48 |
| ▸ | TP53 | P04637 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | GAA | P10253 | 2/20 | 0.45 |
| ▸ | LMNA | P02545 | 2/20 | 0.45 |
| ▸ | MAPT | P10636 | 2/20 | 0.45 |
| ▸ | JAK2 | O60674 | 1/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.44 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.42 |
| ▸ | HSD17B3 | P37058 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29607284 | 0.87 | ELANE (0.74) | ELANELMNAMAPTNPSR1 | |
| SCHEMBL16236834 | 0.85 | ELANE (0.57) | ELANECA1CA2TP53TSHR | |
| SCHEMBL20306504 | 0.83 | ELANE (0.54) | ELANETP53LMNAMAPTNPSR1 | |
| SCHEMBL18785883 | 0.82 | ESR1 (0.57) | ELANEGAAMAPTJAK2POLB | |
| SCHEMBL13212295 | 0.82 | ELANE (0.45) | ELANECA1CA2TP53TSHR | |
| SCHEMBL16239664 | 0.82 | ELANE (0.67) | ELANELMNAMAPTNPSR1 | |
| SCHEMBL18826306 | 0.80 | THRB (0.55) | ELANECA1CA2LMNAMAPT | |
| SCHEMBL19400650 | 0.80 | ELANE (0.51) | ELANECA2GAALMNAMAPT | |
| SCHEMBL19558330 | 0.80 | ELANE (0.51) | ELANECA1CA2TP53TSHR | |
| SCHEMBL6371241 | 0.80 | ELANE (0.44) | ELANECA1CA2TP53TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2872538-B1 | ZIEGLER-NATTA CATALYST SYSTEMS COMPRISING A 1,2-PHENYLENEDIOATE AS INTERNAL DONOR AND PROCESS FOR PREPARING THE SAME | INDIAN OIL CORP LTD (IN) | 2020-03-11 | — | — | EP | disclosed |
| US-9914789-B2 | Ziegler-natta catalyst systems comprising a 1,2-phenylenedioate as internal donor and process for preparing the same | INDIAN OIL CORPORATION LIMITED (IN) | 2018-03-13 | — | — | US | disclosed |
| US-9869931-B2 | Resist composition and patterning process | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 2018-01-16 | — | — | US | disclosed |
| US-9593172-B2 | Ziegler-natta catalyst systems comprising a 1,2-phenylenedioate as internal donor and process for preparing the same | INDIAN OIL CORPORATION LIMITED (IN) | 2017-03-14 | — | — | US | disclosed |
| US-20160347880-A1 | ZIEGLER-NATTA CATALYST SYSTEMS COMPRISING A 1,2-PHENYLENEDIOATE AS INTERNAL DONOR AND PROCESS FOR PREPARING THE SAME | INDIAN OIL CORPORATION LIMITED (IN) | 2016-12-01 | — | — | US | disclosed |
| CN-104755510-A | Ziegler-Natta catalyst systems comprising a 1,2-phenylenedioate as internal donor and process for preparing the same | INDIAN OIL CORP LTD | 2015-07-01 | — | — | CN | disclosed |
| US-20150152199-A1 | ZIEGLER-NATTA CATALYST SYSTEMS COMPRISING A 1,2-PHENYLENEDIOATE AS INTERNAL DONOR AND PROCESS FOR PREPARING THE SAME | INDIAN OIL CORPORATION LIMITED (IN) | 2015-06-04 | — | — | US | disclosed |
| EP-2872538-A1 | ZIEGLER-NATTA CATALYST SYSTEMS COMPRISING A 1,2-PHENYLENEDIOATE AS INTERNAL DONOR AND PROCESS FOR PREPARING THE SAME | Indian Oil Corporation Ltd (IN) | 2015-05-20 | — | — | EP | disclosed |
| WO-2014013401-A1 | ZIEGLER-NATTA CATALYST SYSTEMS COMPRISING A 1,2-PHENYLENEDIOATE AS INTERNAL DONOR AND PROCESS FOR PREPARING THE SAME | INDIAN OIL CORPORATION LIMITED (IN) | 2014-01-23 | — | — | WO | disclosed |
| EP-1434762-B1 | 4'-METHANESULFONYL-BIPHENYL DERIVATIVES AS A HIGHLY SELECTIVE CYCLOOXYGENASE-2 INHIBITOR | CHEIL JEDANG CORP (KR) | 2006-12-20 | — | — | EP | disclosed |
| CN-1245382-C | 4'-methanesulfonyl-biphenyl derivatives as a highly selective cyclooxygenase-2 inhibitor | CHEIL JEDANG CORP (KR) | 2006-03-15 | — | — | CN | disclosed |
| EP-1434762-A4 | 4'-METHANESULFONYL-BIPHENYL DERIVATIVES AS A HIGHLY SELECTIVE CYCLOOXYGENASE-2 INHIBITOR | CHEIL JEDANG CORP (KR) | 2006-01-04 | — | — | EP | disclosed |
| CN-1568309-A | 4'-methanesulfonyl-biphenyl derivatives as a highly selective cyclooxygenase-2 inhibitor | CHEIL JEDANG CORP (KR) | 2005-01-19 | — | — | CN | disclosed |
| EP-1434762-A1 | 4'-METHANESULFONYL-BIPHENYL DERIVATIVES AS A HIGHLY SELECTIVE CYCLOOXYGENASE-2 INHIBITOR | Cheil Jedang Corporation (KR) | 2004-07-07 | — | — | EP | disclosed |
| US-6583321-B1 | Nonsteroid, antiinflammatory; side effect reduction | CHEIL JEDANG CORPORATION (KR) | 2003-06-24 | — | — | US | disclosed |
| US-20030105095-A1 | 4'-Methanesulfonyl-biphenyl derivatives as a highly selective cyclooxygenase-2 inhibitor | CHEIL JEDANG CORPORATION (KR) | 2003-06-05 | — | — | US | disclosed |
| WO-2003031398-A1 | 4'-METHANESULFONYL-BIPHENYL DERIVATIVES AS A HIGHLY SELECTIVE CYCLOOXYGENASE-2 INHIBITOR | CHEIL JEDANG CORPORATION (KR) | 2003-04-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030105095-A1 | 4'-Methanesulfonyl-biphenyl derivatives as a highly selective cyclooxygenase-2 inhibitor | PTGS1, PTGS2, PTGES2 | ELANE 4245/4885CA1 2401/4885CA2 541/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.